Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404755 · ClinicalTrials.gov registry record · Phase 4
Dichotic Listening as a Predictor of Medication Response in Depression
A Phase 4 study of Major Depressive Disorder and Dysthymia, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT00404755: Completed Phase 4 study of Major Depressive Disorder and Dysthymia, sponsored by New York State Psychiatric Institute.
NCT00404755 is a Phase 4 study of Major Depressive Disorder and Dysthymia that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 17 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00404755, a Phase 4 study of Major Depressive Disorder and Dysthymia, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) and preferences of hemispheric laterality in perceptual processing are also found with a different type of commonly used anti-depressant, bupropion.
Primary Outcome
Hamilton Depression Scale, 21 item version Summary of all 21 items and higher score means worse depression. Scores range from 0 to a maximum of 63.
Conditions Studied
Interventions
- DRUG escitalopram
- DRUG bupropion
- DRUG imipramine
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
What the finished NCT00404755 record still lists
NCT00404755 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 3 interventions - of which escitalopram is the first listed.
NCT00404755 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00404755 about?
NCT00404755 is a clinical study titled "Dichotic Listening as a Predictor of Medication Response in Depression". This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) and preferences of hemispheric laterality in perceptual processing are also found with a different ty...
What is the current status of trial NCT00404755?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2006-07. Estimated completion is 2011-08.
What conditions does trial NCT00404755 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Dysthymia.
What interventions are being tested in trial NCT00404755?
The interventions under investigation include: escitalopram (DRUG), bupropion (DRUG), imipramine (DRUG).
Who is sponsoring clinical trial NCT00404755?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00404755 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00404755's enrollment target sits among peer trials
17 254th of 282 higher than 27 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia